Clinical Trial Update: Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This document reports results from a Phase 2 trial of second-line erlotinib plus digoxin in non-small cell lung cancer. The study was terminated and results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DIGOXIN (Digoxin)
• Tarceva (erlotinib)

Snippet

Sponsor: University of Louisville | Conditions: Carcinoma, Non-Small Cell Lung | Phase 2 | Status: TERMINATED | Results posted: 2014-11-10